Search

Your search keyword '"Baggott, Christina"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Baggott, Christina" Remove constraint Author: "Baggott, Christina" Journal transplantation and cellular therapy Remove constraint Journal: transplantation and cellular therapy
21 results on '"Baggott, Christina"'

Search Results

1. Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy

2. Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia: A Merged Analysis from the Pediatric Real-World CAR Consortium (PRWCC) and Pediatric Health Information System (PHIS)

3. Risk Factors for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

5. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia

6. Mediport Use As an Acceptable Standard for CAR T Cell Infusion

7. High Disease Burden and Severe Neutropenia Predict HLH Toxicity in Patients with B-Acute Lymphoblastic Leukemia (B-ALL) Treated with Tisagenlecleucel in the PRWCC

8. LBA1 - CAR-Associated Hemophagocytic Lymphohistiocytosis (HLH) with Use of Commercial Tisagenlecleucel in the Pediatric Real World CAR Consortium (PRWCC): Risk Factors and Outcomes

9. CAR-Associated Hemophagocytic Lymphohistiocytosis (HLH) with Use of Commercial Tisagenlecleucel in the Pediatric Real World CAR Consortium (PRWCC): Risk Factors and Outcomes

10. Real-World Use of Tisagenlecleucel in Infant Acute Lymphoblastic Leukemia

11. Real-World Treatment of Pediatric Patients with Relapsed/Refractory CNS B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel

12. Immune Reconstitution and Infections in the Real-World Use of Tisagenlecleucel in Pediatric and Young Adult ALL

13. Post-Relapse Outcomes Following Tisagenlecleucel: Poor Survival, Despite Current Salvage Therapies: Results from the Pediatric Real World CAR Consortium (PRWCC)

14. Predictive Value of Next-Generation Sequencing (NGS) Following Tisagenlecleucel in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia

15. 262 - High Disease Burden and Severe Neutropenia Predict HLH Toxicity in Patients with B-Acute Lymphoblastic Leukemia (B-ALL) Treated with Tisagenlecleucel in the PRWCC

16. 254 - Mediport Use As an Acceptable Standard for CAR T Cell Infusion

17. 405 - Immune Reconstitution and Infections in the Real-World Use of Tisagenlecleucel in Pediatric and Young Adult ALL

18. 241 - Predictive Value of Next-Generation Sequencing (NGS) Following Tisagenlecleucel in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia

19. 224 - Real-World Treatment of Pediatric Patients with Relapsed/Refractory CNS B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel

20. 126 - Post-Relapse Outcomes Following Tisagenlecleucel: Poor Survival, Despite Current Salvage Therapies: Results from the Pediatric Real World CAR Consortium (PRWCC)

21. 76 - Real-World Use of Tisagenlecleucel in Infant Acute Lymphoblastic Leukemia

Catalog

Books, media, physical & digital resources